An observational study in ADHD, sponsored by Duke University. Not yet recruiting at 1 site in United States. Open to female participants aged 11 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Duke University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Attention Deficit Disorder with Hyperactivity by Duke University — 3 open to participants now, 3 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Duke University.
Among the 19 studies in Attention Deficit Disorder with Hyperactivity by Duke University, this one is the only one that started in 2026, is one of 5 observational ones, and was the 19th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →3 of the 19 studies in Attention Deficit Disorder with Hyperactivity by Duke University are open now, in 2 countries. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 6–9
Duke University · Sites in United States, Canada
Ages 0–20 · Healthy volunteers
By country, each count listing its studies:
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 11 Years to 15 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 127 across 329 observational studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 33 across the 14 interventional studies, 101 across the 5 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 273 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.
2 of the studies in Attention Deficit Disorder with Hyperactivity by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07805382Duke UniversityDynamic Relationships Between Estrogen Fluctuations, Sleep, and Psychiatric Complexity Among Adolescent Females With ADHD | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Attention Deficit Disorder with Hyperactivity by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to establish the feasibility of collecting estradiol (E2), Garmin-measured sleep, and ecological momentary assessments (EMA) of ADHD and related symptoms (mood, anxiety, executive functioning) across menstrual cycles among 20 peripubertal female adolescents aged 11-15 with ADHD, and to explore links between within-individual E2 variability, sleep, and EMA-derived outcomes.
The overall objective is to establish the feasibility of collecting estradiol (E2), Garmin-measured sleep, and ecological momentary assessments (EMA) of ADHD and related symptoms (mood, anxiety, executive functioning) among adolescent females with Attention Deficit Hyperactivity Disorder (ADHD) and explore the links between within-individual E2 variability and EMA-derived outcomes, across menstrual cycles in this population. We aim to establish sufficient pilot data to support a large-scale study focused on characterizing relationships between E2 across the menstrual cycle, sleep, ADHD symptoms, and related symptomatology in adolescent females with ADHD. Participants will complete an initial screening visit answering questionnaires related to puberty, ADHD, and sleep to establish eligibility. After completing a device training session, we will ask participants to provide daily urine E2 samples and EMA brief assessments of ADHD and related clinical features (i.e., mood, executive functioning, sleep) over 2 menstrual cycles (\~56 days). Sleep will be assessed continuously over the study period via convenient wearable (Garmin watch). Feasibility of protocol will be assessed as days of successful E2 data collection, EMA completion, and Garmin wear. Feasibility benchmark=80% actual/anticipated data collection. Multilevel modeling will explore the relationship between within-person changes in E2, ADHD symptoms and related clinical outcomes, and whether sleep strengthens (moderates) these relationships.
Female adolescents ages 11-15 with ADHD in the Duke University Health System
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will complete an initial screening visit answering questionnaires related to puberty, ADHD, sleep, and psychiatric health to establish eligibility. After completing a device training session, participants will be asked to provide daily urine E2 samples and EMA brief assessments of ADHD and related clinical features (i.e., mood, executive functioning, sleep) over 2 menstrual cycles (\~56 days).
Feasibility of Collecting Estradiol (E2)
The percentage of actual E2 data collected compared to anticipated E2 data collected
Time frame: 56 Days
Feasibility of Collecting Garmin Data
The percentage of actual Garmin data collected compared to anticipated Garmin data collected
Time frame: 56 Days
Feasibility of Collecting Ecological Momentary Assessments (EMA)
The percentage of actual EMA data collected compared to anticipated EMA data collected
Time frame: 56 Days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.
Of 85 non-industry observational studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 69. This study's planned 8 months is below that.
Counting every sponsor, half of 95 studies reached it within 35 months; a quarter within 20 and three quarters within 69.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →